osimertinib
astrazeneca
['adaura', 'osimertinib']
dr tsuboi: updates from adaura. ongoing dfs improvement after 36 months osimertinib or placebo, hr 0.23! cns recurrence continues to be higher in placebo group. await os update, but certainly am ongoing strong signal in all stages and regardless of chemo use #esmo22 
Medical Oncologist, Translational Researcher, Peter Mac. Tweets are my own opinions. Musician (@mayhemtomi) https://t.co/f3ccD2Ml7v